Precigen is a high-asymmetry biotech transition story: a newly commercial orphan-drug monopoly with explosive launch revenue, powerful IP protection, and meaningful pipeline optionality, but material execution, debt, and concentration risks.
Overview
Precigen has transformed into a commercial-stage precision medicine company anchored by PAPZIMEOS, the first FDA-approved drug for recurrent respiratory papillomatosis. The therapy targets the root viral cause of RRP and may sharply reduce repeated airway surgeries, creating a compelling orphan-market opportunity. Revenue is primarily U.S.-focused today, supported by PAPZIMEOS sales, Exemplar services, and collaborations, with future growth tied to broader physician adoption, payer coverage, European expansion, and oncology/UltraCAR-T pipeline progress.